Jennifer L Amos
Nurse Practitioner · Alameda
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 9 years
- Graduated 2017
Offices
2 locations
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jennifer L Amos’s office to ask if they take your plan before you enroll.
Medicaid work
$34,180 in 2024
Medicaid paid $34,180 for 132 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 88 | $22,759 |
| Long return visit (40+ min) | 44 | $11,421 |
| 2024 | 132 | 2 | 17 | $34,180 |
| 2023 | 42 | 3 | 14 | $9,821 |
| 2021 | 285 | 3 | 40 | $17,818 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 14 | $3,588 |
| Psychiatric diagnostic evaluation with medical services | 12 | $3,172 |
| Return visit (30+ min) | 16 | $3,060 |
2021
| Clinic visit/encounter, all-inclusive | 127 | $15,969 |
| Short return visit | 101 | $1,849 |
| Short return visit (20+ min) | 57 | $0 |
Drugs they prescribed that Part D paid
$161,668
Pharmacies billed $161,668 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 239) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
188 generic and 51 brand-name prescriptions · $161,668 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rexulti | 25 | $36,516 | $1,461 |
| Trintellix | 11 | $5,437 | $494 |
| Hydroxyzine Pamoate | 13 | $926 | $71 |
| Quetiapine | 33 | $340 | $10 |
| Gabapentin | 17 | $178 | $10 |
See all 7 drugs
| Rexulti | 25 | $36,516 | $1,461 |
| Trintellix | 11 | $5,437 | $494 |
| Hydroxyzine Pamoate | 13 | $926 | $71 |
| Quetiapine | 33 | $340 | $10 |
| Gabapentin | 17 | $178 | $10 |
| Propranolol | 15 | $164 | $11 |
| Metformin | 14 | $37 | $3 |
Year by year
| 2024 | 239 | 14 | 0% (0) | 21% | $161,668 |
| 2023 | 127 | 11 | 0% (0) | 22% | $139,123 |
| 2022 | 690 | 123 | 0% (0) | 12% | $194,205 |
| 2021 | 2,013 | 162 | 0% (0) | 14% | $632,825 |
| 2020 | 560 | 51 | 0% (0) | 9% | $124,823 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Invega Sustenna | 14 | $38,640 | $2,760 |
| Quetiapine | 15 | $384 | $26 |
| Propranolol | 11 | $142 | $13 |
| Metformin | 11 | $37 | $3 |
2022: 23 drugs
| Invega Sustenna | 23 | $63,989 | $2,782 |
| Latuda | 18 | $37,646 | $2,091 |
| Abilify Maintena | 12 | $27,674 | $2,306 |
| Aripiprazole | 27 | $4,721 | $175 |
| Olanzapine | 41 | $2,929 | $71 |
| Divalproex Sodium Er | 38 | $1,838 | $48 |
| Asenapine Maleate | 11 | $1,664 | $151 |
| Clozapine | 13 | $1,242 | $96 |
| Quetiapine | 55 | $976 | $18 |
| Quetiapine Fumarate Er | 12 | $911 | $76 |
| Bupropion Xl | 24 | $731 | $30 |
| Risperidone | 47 | $681 | $14 |
| Benztropine Mesylate | 37 | $357 | $10 |
| Haloperidol | 13 | $338 | $26 |
| Buspirone | 25 | $315 | $13 |
| Divalproex | 13 | $311 | $24 |
| Fluoxetine | 21 | $261 | $12 |
| Trazodone | 23 | $241 | $10 |
| Sertraline | 23 | $183 | $8 |
| Topiramate | 12 | $175 | $15 |
| Lorazepam | 19 | $102 | $5 |
| Escitalopram | 16 | $89 | $6 |
| Zolpidem | 11 | $33 | $3 |
2021: 39 drugs
| Invega Sustenna | 122 | $315,824 | $2,589 |
| Latuda | 68 | $109,768 | $1,614 |
| Abilify Maintena | 15 | $34,909 | $2,327 |
| Risperdal Consta | 21 | $22,349 | $1,064 |
| Divalproex Sodium Er | 66 | $5,405 | $82 |
| Paliperidone Er | 16 | $4,240 | $265 |
| Bupropion Xl | 115 | $3,964 | $34 |
| Aripiprazole | 85 | $3,846 | $45 |
| Olanzapine | 113 | $3,453 | $31 |
| Clozapine | 32 | $2,095 | $65 |
| Quetiapine | 155 | $1,976 | $13 |
| Desvenlafaxine Succinate Er | 15 | $1,609 | $107 |
| Trazodone | 116 | $1,603 | $14 |
| Duloxetine | 57 | $1,480 | $26 |
| Prazosin | 26 | $1,402 | $54 |
| Buspirone | 63 | $1,037 | $16 |
| Risperidone | 72 | $847 | $12 |
| Benztropine Mesylate | 68 | $846 | $12 |
| Fluoxetine | 95 | $835 | $9 |
| Sertraline | 63 | $815 | $13 |
| Propranolol | 34 | $774 | $23 |
| Quetiapine Fumarate Er | 12 | $628 | $52 |
| Haloperidol | 22 | $623 | $28 |
| Doxepin | 22 | $538 | $24 |
| Escitalopram | 66 | $482 | $7 |
| Divalproex | 15 | $353 | $24 |
| Hydroxyzine Pamoate | 32 | $285 | $9 |
| Lithium Carbonate Er | 16 | $271 | $17 |
| Venlafaxine Hcl Er | 38 | $266 | $7 |
| Lithium Carbonate | 22 | $239 | $11 |
| Hydroxyzine | 14 | $235 | $17 |
| Topiramate | 41 | $219 | $5 |
| Bupropion Hcl Sr | 11 | $205 | $19 |
| Gabapentin | 20 | $164 | $8 |
| Zolpidem | 11 | $158 | $14 |
| Lorazepam | 19 | $148 | $8 |
| Lamotrigine | 19 | $137 | $7 |
| Citalopram Hbr | 26 | $114 | $4 |
| Clonazepam | 15 | $84 | $6 |
2020: 18 drugs
| Invega Sustenna | 29 | $72,791 | $2,510 |
| Latuda | 17 | $26,646 | $1,567 |
| Divalproex Sodium Er | 21 | $2,626 | $125 |
| Bupropion Xl | 45 | $1,481 | $33 |
| Aripiprazole | 17 | $1,467 | $86 |
| Olanzapine | 43 | $1,360 | $32 |
| Trazodone | 22 | $805 | $37 |
| Quetiapine | 53 | $702 | $13 |
| Duloxetine | 19 | $604 | $32 |
| Buspirone | 21 | $554 | $26 |
| Prazosin | 15 | $491 | $33 |
| Propranolol | 18 | $482 | $27 |
| Fluoxetine | 33 | $354 | $11 |
| Benztropine Mesylate | 20 | $256 | $13 |
| Hydroxyzine Pamoate | 18 | $176 | $10 |
| Escitalopram | 18 | $160 | $9 |
| Venlafaxine Hcl Er | 14 | $122 | $9 |
| Sertraline | 14 | $104 | $7 |
Money from drug and device companies
$1,307 in 2025
| 2025 | 8 | 53 | None | $1,307 |
| 2024 | 9 | 47 | None | $995 |
| 2023 | 8 | 29 | None | $1,458 |
| 2022 | 8 | 40 | None | $2,150 |
| 2021 | 9 | 27 | None | $1,361 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurocrine BioSciences | Ingrezza | $479 | 16 payments
|
| Teva Pharmaceuticals USA | Uzedy | $250 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $240 | 10 payments
|
| Otsuka America Pharmaceutical | Rexulti | $161 | 8 payments
|
| Vanda Pharmaceuticals | Fanapt | $102 | 6 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $40 | 1 payment
|
See all 53 published payments
| Teva Pharmaceuticals USA | Meals · 2025-12-18 | Uzedy | $16 |
| Vanda Pharmaceuticals | Meals · 2025-12-17 | Fanapt | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-12 | Cobenfy | $25 |
| Teva Pharmaceuticals USA | Meals · 2025-12-10 | Uzedy | $17 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-04 | Cobenfy | $4 |
| Otsuka America Pharmaceutical | Meals · 2025-12-04 | Abilify Maintena | $23 |
| Luye Pharma (USA) | Meals · 2025-12-04 | Erzofri Extended-Release | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-12-04 | Austedo Xr | $4 |
| Vanda Pharmaceuticals | Meals · 2025-11-20 | Fanapt | $16 |
| Pfizer | Meals · 2025-11-19 | Nurtec Odt | $20 |
| Neurocrine BioSciences | Meals · 2025-11-19 | Ingrezza | $32 |
| Otsuka America Pharmaceutical | Meals · 2025-11-13 | Rexulti | $27 |
| Neurocrine BioSciences | Meals · 2025-11-05 | Ingrezza | $36 |
| Neurocrine BioSciences | Meals · 2025-10-30 | Ingrezza | $36 |
| Teva Pharmaceuticals USA | Meals · 2025-10-29 | Uzedy | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-23 | Cobenfy | $4 |
| Otsuka America Pharmaceutical | Meals · 2025-10-23 | Abilify Maintena | $19 |
| Neurocrine BioSciences | Meals · 2025-10-22 | Ingrezza | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-06-04 | Abilify Maintena | $21 |
| Neurocrine BioSciences | Meals · 2025-05-29 | Ingrezza | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-22 | Cobenfy | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-05-15 | Rexulti | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-05-15 | Rexulti | $6 |
| Janssen Pharmaceuticals | Meals · 2025-05-09 | Invega Sustenna | $40 |
| Neurocrine BioSciences | Meals · 2025-05-08 | Ingrezza | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-02 | Cobenfy | $38 |
| Vanda Pharmaceuticals | Meals · 2025-05-01 | Fanapt | $15 |
| Neurocrine BioSciences | Meals · 2025-04-30 | Ingrezza | $34 |
| Otsuka America Pharmaceutical | Meals · 2025-04-24 | Rexulti | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-10 | Cobenfy | $31 |
| Teva Pharmaceuticals USA | Education · 2025-04-10 | None | $104 |
| Teva Pharmaceuticals USA | Meals · 2025-04-09 | Uzedy | $19 |
| Neurocrine BioSciences | Meals · 2025-04-03 | Ingrezza | $37 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-20 | Cobenfy | $29 |
| Teva Pharmaceuticals USA | Meals · 2025-03-19 | Austedo Xr | $5 |
| Teva Pharmaceuticals USA | Meals · 2025-03-19 | Uzedy | $2 |
| Teva Pharmaceuticals USA | Meals · 2025-03-19 | Uzedy | $23 |
| Vanda Pharmaceuticals | Meals · 2025-03-12 | Fanapt | $15 |
| Neurocrine BioSciences | Meals · 2025-03-05 | Ingrezza | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-27 | Cobenfy | $24 |
| Neurocrine BioSciences | Meals · 2025-02-26 | Ingrezza | $30 |
| Neurocrine BioSciences | Meals · 2025-02-20 | Ingrezza | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-13 | Cobenfy | $37 |
| Neurocrine BioSciences | Meals · 2025-02-12 | Ingrezza | $32 |
| Vanda Pharmaceuticals | Meals · 2025-02-07 | Fanapt | $22 |
| Neurocrine BioSciences | Meals · 2025-02-06 | Ingrezza | $33 |
| Neurocrine BioSciences | Meals · 2025-01-29 | Ingrezza | $16 |
| Teva Pharmaceuticals USA | Meals · 2025-01-24 | Uzedy | $31 |
| Neurocrine BioSciences | Meals · 2025-01-23 | Ingrezza | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-01-22 | Abilify Asimtufii | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-16 | Cobenfy | $20 |
| Vanda Pharmaceuticals | Meals · 2025-01-10 | Fanapt | $21 |
| Neurocrine BioSciences | Meals · 2025-01-09 | Ingrezza | $26 |
See earlier years (2024, 2023, 2022, 2021)
2024: $995
| Teva Pharmaceuticals USA | Austedo Xr | $319 | 20 payments
|
| Vanda Pharmaceuticals | Fanapt | $274 | 11 payments
|
| Neurocrine Biosciences | Ingrezza | $143 | 5 payments
|
| Otsuka America Pharmaceutical | Rexulti | $100 | 4 payments
|
| Tempus AI | Tempus Pixel | $50 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $43 | 2 payments
|
| Lundbeck | Rexulti | $34 | 1 payment
|
| Abbvie | Vraylar | $17 | 1 payment
|
| Alkermes | Aristada | $15 | 1 payment
|
2023: $1,458
| Teva Pharmaceuticals USA | Austedo Xr | $461 | 11 payments
|
| Abbvie | Vraylar | $422 | 6 payments
|
| Alkermes | Aristada | $312 | 5 payments
|
| Neurocrine Biosciences | Ingrezza | $173 | 3 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $29 | 1 payment
|
| Indivior | Perseris | $25 | 1 payment
|
| Janssen Pharmaceuticals | Invega Trinza | $21 | 1 payment
|
| Lundbeck | Rexulti | $16 | 1 payment
|
2022: $2,150
| Otsuka America Pharmaceutical | Rexulti | $417 | 7 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $395 | 14 payments
|
| Neurocrine Biosciences | Ingrezza | $357 | 6 payments
|
| Teva Pharmaceuticals USA | Austedo | $306 | 4 payments
|
| Abbvie | Vraylar | $256 | 3 payments
|
| Alkermes | Aristada | $243 | 3 payments
|
| Iti | Caplyta | $119 | 1 payment
|
| Indivior | Perseris | $58 | 2 payments
|
2021: $1,361
| Janssen Pharmaceuticals | Invega Sustenna | $399 | 8 payments
|
| Neurocrine Biosciences | Ingrezza | $398 | 5 payments
|
| Alkermes | Lybalvi | $216 | 5 payments
|
| AbbVie | Vraylar | $170 | 4 payments
|
| CSL Behring | Kcentra | $111 | 1 payment
|
| Iti | Caplyta | $22 | 1 payment
|
| Sunovion Pharmaceuticals | Latuda | $21 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $19 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $6 | 1 payment
|
Professional record
- NPI
- 1043761000
- Licence
- CA NP95009983
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 3835 N Freeway Blvd Ste 100, Sacramento, CA, 95834
- NPI first listed
- 2016-10-14
- NPI last updated
- 2026-04-28
- NPI record certified
- 2026-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 12141 Brookhurst St, Garden Grove, CA, 92840